Dr Martens has reaffirmed its full-year guidance for fiscal 2027, citing encouraging wholesale demand in the United States, its largest market.
The UK-based footwear manufacturer stated that trading performance since the start of the period has aligned with internal expectations, providing a counterpoint to recent volatility in the consumer discretionary sector.
The decision to maintain the outlook suggests that the brand’s direct-to-consumer and wholesale channels are holding up well against potential softening in consumer spending.
US wholesale orders, a key leading indicator for the company’s revenue trajectory, have remained robust, supporting the firm’s confidence in its annual targets.
This stability comes as global supply chains and consumer sentiment face ongoing pressures.
While peers in the apparel and footwear space have grappled with inventory adjustments and shifting demand patterns, Dr Martens appears to be leveraging its strong brand equity to sustain momentum.